Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California
This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.
52-Week MINT Data Confirm Inebilizumab Benefit in AChR+ gMG: Richard Nowak, MD, MS
Vedolizumab First Shows Clinical and Economic Advantage in Ulcerative Colitis
US Pharmaceutical Pipeline Expands With Innovation and Competition
Hospital-Based Addiction Consultation Addresses Gaps, Improves Treatment Rate